Product Information
OXYBUTYNIN 5 MG TABLET is a generic product labeled by Leading Pharma, LLC, priced at $0.0480 per EA under NDC 69315018210. Its NADAC has been published 262 times since Sep 29, 2021.
FDA first approved this application on Apr 6, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Leading Pharma, LLCNDC
69315018210
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OXYBUTYNIN CHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA212798FDA Approved
4/6/2020
TE Code
AB
On Market Since
11/1/2019
Pharmacological Classes
Price Statistics
The NADAC for OXYBUTYNIN 5 MG TABLET has been published 262 times since Sep 29, 2021, and over the history we have for it it has declined 37.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0480 per EA |
|---|---|
| All-time high | $0.0786 (Apr 13, 2022) |
| All-time low | $0.0448 (Nov 20, 2024) |
| 52-week high | $0.0492 |
| 52-week low | $0.0455 |
| Median price | $0.0547 |
| Average price | $0.0587 |
| Largest weekly change | -28.1% (Apr 17, 2024) |
| Weeks tracked | 262 |
| Tracking since | Sep 29, 2021 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Leading Pharma, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
OXYBUTYNIN CHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinergic Muscarinic Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OXYBUTYNIN 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for OXYBUTYNIN 5 MG TABLET, manufactured by Leading Pharma, LLC, is $0.0480 per EA (NDC 69315018210), effective Sep 30, 2026.
How has the price of OXYBUTYNIN 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for OXYBUTYNIN 5 MG TABLET has declined 37.0%. It has been tracked across 262 weekly CMS publications since Sep 29, 2021.
What are the highest and lowest recorded NADAC prices for OXYBUTYNIN 5 MG TABLET?
Since Sep 29, 2021, the NADAC for OXYBUTYNIN 5 MG TABLET has ranged from a low of $0.0448 (Nov 20, 2024) to a high of $0.0786 (Apr 13, 2022), with a median of $0.0547 per EA.
Are there cheaper alternatives to OXYBUTYNIN 5 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as OXYBUTYNIN 5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures OXYBUTYNIN 5 MG TABLET?
OXYBUTYNIN 5 MG TABLET (NDC 69315018210) is labeled by Leading Pharma, LLC, and CMS classifies it as a generic product.